Victoza Archives -

Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of

Novo Nordisk hints at US price cuts after Q2 sales fall

https://pharmaphorum.com/news/novo-nordisk-price-reductions/

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight

Novo’s diabetes pill beats injections in head-to-head trials

https://pharmaphorum.com/news/novo-nordisks-success-with-oral-diabetes-drug/

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers. It needs next generation

Novo Nordisk: survival of the fittest applies in diabetes and obesity market

https://pharmaphorum.com/views-and-analysis/novo-nordisk-survival-fittest-applies-diabetes-obesity-market/

Two diabetes drugs, Lilly and Boehringer Ingelheim’s (BI) Jardiance and Novo Nordisk’s Victoza, have shown they can go

The ‘game changers’ in diabetes: Novo and Lilly battle it out

https://pharmaphorum.com/views-and-analysis/diabetes-drugs-prevent-heart-attacks-strokes-novo-lilly-battle/

Pharmacy benefit managers and arrival of biosimilars making life difficult for diabetes companies

Novo posts strong performance, but US pricing pressure grows

https://pharmaphorum.com/news/novo-posts-strong-performance-warns-us-pricing-pressure/

Victoza results are significant, but fell short of investors’ expectations.

Victoza disappoints on cardio benefits, lifts rival Jardiance

https://pharmaphorum.com/news/novo-boehringerlilly-vying-cardio-benefit-diabetes/

Largest and longest trial ever conducted by the company

Novo Nordisk buoyed by Victoza cardiovascular results

https://pharmaphorum.com/news/novo-nordisk-buoyed-by-victoza-cardiovascular-results/

Victoza